For research and educational purposes only. PepTalk discusses what researchers study in laboratory settings — not medical advice. Products are sold for laboratory research use only.
Research Peptide
GCG/GLP Survo
An investigational dual GLP-1 / glucagon agonist studied for metabolic and liver-disease research — earlier in the pipeline than the incretin leaders. Freeze-dried, ultra-pure, ready to reconstitute.
For research and educational purposes only. PepTalk discusses what researchers study in laboratory settings — not medical advice. Products are sold for laboratory research use only.
The short version
Survo is a single peptide built to switch on two of the body's own metabolic receptors at once — GLP-1 and glucagon. That second pathway sets it apart from the incretin compounds most people know: instead of the GIP receptor that the dual- and triple-agonists use, Survo pairs GLP-1 with glucagon, a combination researchers study as much for fatty-liver disease as for body weight. It's an earlier-stage, investigational compound — promising in models, with Phase 2 human data still being built out.
What researchers are looking at
The body manages hunger, blood sugar, and how fat is stored and burned through a set of gut and pancreatic hormones. Most research compounds in this space lean on the GLP-1 messenger, sometimes paired with a second one called GIP. Survo takes a different route — it pairs GLP-1 with glucagon instead, and that pairing is the part researchers find most interesting.
The two arms are studied for different jobs. The GLP-1 side is the familiar one: in models it slows how quickly the stomach empties and signals fullness to the brain. The glucagon side is the novel addition — in published models it's associated with higher energy expenditure and with clearing fat out of the liver, rather than acting on appetite alone. That liver angle is why a large part of Survo's research sits in MASH/NASH (fatty-liver disease) on top of obesity.
Because Survo is earlier in the pipeline than the incretin leaders, most of the standout findings come from animal and modeling work, with Phase 2 trials now reporting in both liver disease and weight management. The figures are best read as what researchers observe in these models and early trials rather than proven outcomes — but having human data in two separate disease areas is what keeps it under active scientific attention.
GLP-1 pathway
Activates the GLP-1 receptor — the satiety pathway familiar from incretin research, studied for slowing gastric emptying and signaling fullness.
Glucagon pathway
Adds the glucagon arm — associated in published models with higher energy expenditure and with clearing fat from the liver.
Liver-fat focus
The two arms together are studied in MASH/NASH fatty-liver models, the research area that sets Survo apart from appetite-only compounds.
Where the evidence stands
an honest mapEnergy-expenditure & liver-fat changes documented in models
Phase 2 data in both liver disease and weight management
From the lab toward the clinic
Survo has reached Phase 2 randomized human trials in two separate areas — MASH/NASH fatty-liver disease and weight management — which is unusual for a compound this early in the pipeline. In the liver-disease work, researchers reported improvements in MASH on histology versus placebo, and the weight-management arm reported meaningful body-weight reductions at the higher concentrations studied. It's genuine human data, but still earlier-stage than the incretin leaders.
At a glance
What it is
A dual-agonist peptide
GLP-1 + glucagon
Studied for
Liver-fat & metabolic research
MASH/NASH + obesity
What sets it apart
Glucagon arm
not the GIP others use
Research stage
Investigational
Phase 2 underway
How it arrives
Lyophilized powder
Ships freeze-dried for stability and shelf life. Before research use, it's reconstituted with bacteriostatic water.
Bacteriostatic water
Needed to reconstitute
Certificate of analysis
Common questions
All products on FastPeps are labeled Research Use Only (RUO), and this is a legal requirement, not just fine print. It means these compounds are sold strictly for scientific research and laboratory purposes, not for personal use, self-administration, or medical treatment. This label exists because these compounds have not completed the FDA approval process to be sold as drugs or supplements. When you purchase from FastPeps, you are agreeing the product is for research purposes only.
For laboratory and research use only. Sold exclusively for in-vitro research and laboratory experimentation. Not a drug, supplement, or article intended for human or veterinary use; nothing here is medical advice or a claim of therapeutic benefit. Statements describe findings from published research.
Your Reliable Source for High-Quality Research Peptides
FastPeps is more than just a trusted U.S. supplier of research peptides. We are a catalyst for scientific advancement, dedicated to providing the highest quality peptides that empower our clients to push the boundaries of research.
